MK1775, a Selective Wee1 Inhibitor, Shows Single-Agent Antitumor Activity against Sarcoma CellsJenny Kreahling(Moffitt Cancer Center), Soner Altiok(Moffitt Cancer Center)Molecular Cancer TherapeuticsNovember 15, 201110.1158/1535-7163.mct-11-0529Cited by 122SaveCiteExport RISWatch citationsRelated PapersPPARγ induces cell cycle withdrawal: inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A|Genes & Development|1997|380Wee1 Inhibition by MK-1775 Leads to Tumor Inhibition and Enhances Efficacy of Gemcitabine in Human Sarcomas|PLoS ONE|2013|89Histone Deacetylase Inhibitors Downregulate Checkpoint Kinase 1 Expression to Induce Cell Death in Non-Small Cell Lung Cancer Cells|PLoS ONE|2010|69